17-39666063-G-A
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BP4_Strong
The NM_003673.4(TCAP):c.458G>A(p.Arg153His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000203 in 1,603,976 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. R153R) has been classified as Likely benign.
Frequency
Consequence
NM_003673.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TCAP | NM_003673.4 | c.458G>A | p.Arg153His | missense_variant | 2/2 | ENST00000309889.3 | NP_003664.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TCAP | ENST00000309889.3 | c.458G>A | p.Arg153His | missense_variant | 2/2 | 1 | NM_003673.4 | ENSP00000312624 | P1 | |
TCAP | ENST00000578283.1 | c.386G>A | p.Arg129His | missense_variant | 3/3 | 5 | ENSP00000462787 |
Frequencies
GnomAD3 genomes AF: 0.000210 AC: 32AN: 152214Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000210 AC: 51AN: 242878Hom.: 0 AF XY: 0.000197 AC XY: 26AN XY: 132260
GnomAD4 exome AF: 0.000202 AC: 293AN: 1451644Hom.: 0 Cov.: 34 AF XY: 0.000205 AC XY: 148AN XY: 722566
GnomAD4 genome AF: 0.000210 AC: 32AN: 152332Hom.: 0 Cov.: 33 AF XY: 0.000255 AC XY: 19AN XY: 74498
ClinVar
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Oct 07, 2015 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p.Arg153His (R153H; c.458G>A) in exon 2 of the TCAP gene (NM_003673.3). The Arg153His variant in TCAP has been previously identified in a Japanese male with HCM as well as in his affected sister (Hayashi 2004). Hayashi et al. also identified Arg153His in the proband's two sons who were asymptomatic at the time of evaluation. The Laboratory for Molecular Medicine at Harvard has reported in ClinVar that they have seen the varint in one Bangledeshi infant with RCM who carried a second variant in an HCM-associated gene. Functional studies in yeast have shown that the Arg153His variant leads to an increase in the ability of TCAP to bind with titin and CS-1 (Hayashi 2004). However, this in vitro assay may not accurately represent biological function. This is a conservative amino acid change, resulting in the replacement of a basic Arginine with a basic Histidine at a location that is poorly conserved across mammalian and vertebrate species. Of note, Histidine is the default amino acid in at least 8 species of mammal, suggesting that this change may be tolerated. Also, no mutations in nearby residues have been reported in association with cardiomyopathy, according to the lab report. According to ExAC, in silico analysis with SIFT or PolyPhen-2 predicts the variant to be tolerated/benign. In total the variant has been seen in 20/60,000 individuals from publicly available population datasets. The variant was not observed in published controls: It was absent from 240 Japanese and 70 Korean control individuals (Hayashi et al. 2004). The variant was detected in 2/8592 European American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs149585781) which currently includes variant calls on ~4300 Caucasian and ~2200 African American individuals. The phenotype of the ESP individuals is not publicly available, however the cohorts that were merged to create this dataset were all either general population samples or samples recruited for common cardiovascular disease such as hypertension. Our patient’s ancestry is African-American. Ancestry-matched individuals can be found in even greater numbers in the ExAC database of 60,000 exomes from disease-specific and population genetic studies (with efforts made to exclude individuals with severe pediatric diseases). ExAC currently contains 5049 African-ancestry individuals. There are 20 individuals in ExAc with this variant and, of these, 17 of them are Caucasian, none of them are African, 2 are East Asian, and 1 is “Other”; this variant is most common in the Finnish population in ExAC with an allele frequency of 0.2%. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jan 14, 2014 | The Arg153His variant in TCAP has been previously identified in an Asian individ ual with HCM as well as in one affected relative (Hayashi 2004). It has now been identified by our laboratory in one Bangledeshi infant with RCM carrying a seco nd variant in an HCM associated gene. The variant was detected in 2/8592 Europea n American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.wash ington.edu/EVS/; dbSNP rs149585781). Functional studies in yeast have shown that the Arg153His variant leads to an increase in the ability of TCAP to bind with titin and CS-1 (Hayashi 2004). However, this in vitro assay may not accurately r epresent biological function. However, arginine (Arg) at position 153 is not con served in evolution and 7 mammals carry the variant amino acid (gorilla, horse, white rhinoceros, shrew, elephant, manatee, wallaby, and platypus), suggesting t hat this change may be tolerated. Additional computational analyses (biochemical amino acid properties, AlignGVGD, PolyPhen2, and SIFT) suggest that the Arg153H is variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the available information is conf licting and additional information is needed to fully assess the clinical signif icance of the Arg153His variant. - |
Hypertrophic cardiomyopathy 25 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 07, 2004 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 21, 2018 | The R153H variant of uncertain significance has been identified in the TCAP gene. The variant has previously been reported in association with HCM and DCM (Hayashi et al., 2004; Akinrinade et al., 2015). Hayashi et al. (2004) identified R153H in a Japanese patient with HCM and his affected sister. The variant was also identified in the proband's two sons, who were asymptomatic at the time of evaluation (Hayashi et al., 2004). Akinrinade et al. (2015) identified R153H in a Finnish patient with DCM. Although the R153H variant was not observed at a significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, it was observed in 13/6,592 (~0.2%) alleles from individuals of European (Finnish) background in Exome Aggregation Consortium (ExAC). In addition, the R153H variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position that is not conserved across species, and Histidine is the wild-type amino acid at this position in multiple species. Furthermore, 2/3 in silico algorithms predict this variant likely does not alter the protein structure/function. - |
Autosomal recessive limb-girdle muscular dystrophy type 2G;C4225408:Hypertrophic cardiomyopathy 25 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 17, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Primary familial hypertrophic cardiomyopathy;C4225408:Hypertrophic cardiomyopathy 25 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at